What the research found
Pauling's historical advocacy for megadose vitamin C was largely dismissed, but recent work has revealed a mechanistic distinction that vindicates part of his intuition—though not in the way he imagined. The critical difference lies in delivery: oral vitamin C supplements maintain relatively modest blood concentrations because of absorption limits in the gut, which explains why pill-based trials failed to show anti-cancer effects. By contrast, intravenous administration bypasses these constraints and achieves circulating levels orders of magnitude higher, apparently triggering biochemical pathways distinct from what occurs with dietary intake.
At these elevated concentrations, vitamin C appears to function more as a pharmacological agent than a micronutrient. Preliminary evidence indicates it can preferentially stress certain cancer cells while leaving normal tissue relatively spared, possibly reduce some treatment-related toxicity, and in limited cases correlate with improved clinical outcomes. The mechanism likely involves oxidative stress generation within malignant cells, though the research remains early-stage.
Why it matters for you
If you're tracking micronutrient status or considering IV therapies as part of a health-optimisation protocol, this reframes how to think about vitamin C dosing and delivery. The finding underscores that bioavailability isn't just about absolute intake—the route fundamentally changes what dose reaches systemic circulation and what biological effects follow. Oral supplementation (the typical form most users consume) operates in a different physiological regime than IV approaches.
For those interested in cancer risk reduction or supporting conventional treatment, this suggests that megadose oral vitamin C is unlikely to replicate IV benefits, despite containing the same molecule. If you're considering IV protocols—increasingly marketed in longevity and integrative medicine spaces—this work provides some mechanistic rationale, though clinical benefit remains unproven outside specific contexts. Standard blood biomarkers of vitamin C status won't capture whether IV therapy is triggering these proposed anti-cancer mechanisms.
Caveats
- Early-stage research; clinical benefit not yet firmly established in humans
- Most existing data from animal models or small, non-randomised studies
- High-dose IV vitamin C carries potential safety considerations (especially in certain populations like those with G6PD deficiency) not addressed here
- Unclear which cancer types, if any, derive meaningful benefit
- Industry interest in IV therapies may bias which studies get funded and published